LONDON, BOSTON, TOKYO (December 10, 2014) — Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year according to EP Vantage’s latest report, “Pharma & Biotech 2015 Preview.” EP Vantage is the editorial arm of market intelligence firm Evaluate Ltd.
“Cancer will also have a huge year as the promise of immuno-oncology therapies are further tested,” said Amy Brown, EP Vantage reporter and report author. “But with payers looking to restrain drug prices, marketed products may face heightened commercialization risks. Nonetheless, if 2015 lives up to today’s heady expectations, it will be a remarkable year that the sector will long remember.”
The “Pharma & Biotech 2015 Preview” report based on market intelligence and consensus forecasts from EvaluatePharma® can be downloaded at www.evaluategroup.com/PharmaBiotech2015PPreview.
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.
Issued for and on behalf of Evaluate Ltd by Instinctif Partners.
For more information please contact: Tel: email@example.com
Melanie Toyne-SewellManaging Partner